A5085285055- Sarcoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Lymphoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Schizophrenia research and treatment
- Cancer Cells and Metastasis
- Statistical Methods in Clinical Trials
- Monoclonal and Polyclonal Antibodies Research
- Gastrointestinal Tumor Research and Treatment
- RNA modifications and cancer
- Childhood Cancer Survivors' Quality of Life
- Statistical Methods and Bayesian Inference
- Protein Degradation and Inhibitors
- Treatment of Major Depression
- Chemotherapy-related skin toxicity
- Radiomics and Machine Learning in Medical Imaging
- Iron Metabolism and Disorders
- Brain Metastases and Treatment
- Biochemical and Molecular Research
- Pancreatic and Hepatic Oncology Research
- Chronic Myeloid Leukemia Treatments
- Neurofibromatosis and Schwannoma Cases
- interferon and immune responses
- Statistical Distribution Estimation and Applications
Harbin Medical University
2025
Third Affiliated Hospital of Harbin Medical University
2025
Ministry of Agriculture and Rural Affairs
2024
Sichuan Agricultural University
2024
Eli Lilly (United States)
2016-2021
Metrum Research Group (United States)
2020
Universidad de Navarra
2018
AstraZeneca (United States)
2014
University at Buffalo, State University of New York
2013-2014
Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In phase study, an benefit in this population was observed the addition olaratumab to doxorubicin over alone.To determine efficacy plus patients advanced/metastatic STS.ANNOUNCE confirmatory, 3, double-blind, randomized trial conducted at 110 sites 25 countries from September 2015 December 2018; final date follow-up 5, 2018. Eligible were anthracycline-naive adults unresectable locally or...
LBA3 Background: Dox is standard therapy in STS. In a Ph 2 trial, olaratumab (a human IgG1 antibody targeting PDGFRα) + dox improved overall survival (OS) and progression-free (PFS) vs dox. ANNOUNCE aimed to confirm the OS benefit advanced Methods: Adult pts with unresectable locally or metastatic STS, anthracycline-naïve, ECOG PS 0-1 were eligible. Pts randomized 1:1 (20mg/kg Cycle 1, 15mg/kg subsequent cycles) PBO on Days 1 8 of each 21-day cycle combined (75mg/m ) Day for up cycles. After...
298 Background: The current TNM staging system fails to provide adequate information for prognosis and adjuvant chemotherapy benefits in colorectal cancer (CRC). Pathomics, an emerging field, shows promise improving estimation decision-making. In this study, we developed validated a pathomics signature (PS CRC ) that directly analyzes hematoxylin eosin–stained slides using deep learning predict outcomes. Methods: A total of 883 whole slide images from two cohorts, Harbin Medical University...
Colon cancer (CC) is a common malignancy with rising incidence worldwide. Despite advances in treatment strategies, many patients still face poor prognosis due to the development of drug resistance. Long non-coding RNAs (lncRNAs) have emerged as important regulators various biological processes and been implicated progression. Among them, colorectal neoplasia differentially expressed (CRNDE) has drawn attention for its potential roles different cancers. However, specific functions CC remain...
Objectives: Rimegepant orally disintegrating tablet (ODT) is indicated for acute treatment of migraine (with and without aura) at 75 mg up to once per day preventive episodic every other (EOD) in adults [1]. The objective this study was refine rimegepant population pharmacokinetic (PPK) model using adult pediatric PK data, predict exposures, provide dosing selection, populations across different age body-weight ranges efficacy safety studies. Methods: An established PPK further developed...
Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-α (PDGFRα). In randomized phase II study, olaratumab plus doxorubicin met its predefined primary endpoint for progression-free survival and achieved highly significant improvement in overall versus alone patients with advanced or metastatic soft tissue sarcoma (STS). this we characterize the pharmacokinetics (PKs) of cancer patient population. was tested at 15 20 mg/kg four studies (in...
To determine optimal sampling strategies to allow the calculation of clinical pharmacokinetic parameters for selected antipsychotic medicines using a pharmacometric approach.This study utilized previous population aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone (including 9-OH risperidone) and ziprasidone. d-optimality was identify time points which accurately predicted (and expected error) each drug at steady-state. A standard two stage approach (STS) with...
Abstract This phase Ib study enumerated whole blood circulating tumor cells (CTC) and evaluated biomarkers in patients with potentially resectable soft-tissue sarcoma (STS) treated olaratumab monotherapy (20 mg/kg) for one cycle followed by up to six cycles of mg/kg, 1–2; 15 3–7) plus doxorubicin (75 mg/m2 on day 1). CTCs, platelet-derived growth factor receptors (PDGFR), PDGF ligand expression tissue pre- post-olaratumab were evaluated. Antitumor activity, safety, pharmacokinetics,...
Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. plus doxorubicin improved survivalversus in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure–response relationship for progression-free survival (PFS), overall (OS), and safety. PFS OS data from 133 patients enrolled study were analysed using time-to-event modelling. The effect of on PFS/OS was explored trough serum concentration after cycle 1 (Cmin1) average...
Xenograft mice are largely used to evaluate the efficacy of oncological drugs during preclinical phases drug discovery and development. Mathematical models provide a useful tool quantitatively characterize tumor growth dynamics also optimize upcoming experiments. To best our knowledge, this is first report where unperturbed large set cell lines (n = 28) has been systematically analyzed using previously proposed model nonlinear mixed effects (NLME). Exponential was identified as governing...
Abstract Somatic gain-of-function mutations in IDH1 have been identified multiple tumor types including AML, glioma, cholangiocarcinoma and chondrosarcoma. The neo-enzymatic activity of mutant results accumulation the oncometabolite 2-hydroxyglutarate (2-HG), leading to a hyper-methylation phenotype, block cell differentiation, growth. Using structure-based drug design approach, we developed highly potent covalent inhibitor IDH1. LY3410738 modifies single cysteine (Cys269) allosteric binding...
Accurate prediction of tumor growth is critical in modeling the effects anti-tumor agents. Popular models inhibition (TGI) generally offer empirical description growth. We propose a lifespan-based (LS TGI) model that describes xenograft mouse model, on basis cellular lifespan T. At end lifespan, cells divide, and to account for burden growth, we introduce cell division efficiency function negatively affected by size. The LS TGI capability describe dynamic characteristics similar many models....
Abstract Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks activation. We conducted phase 1 trial evaluate the safety of olaratumab determine recommended dose in combination with three different chemotherapy regimens children. Patients <18 years relapsed/refractory solid or central nervous system tumors were enrolled two levels olaratumab. received monotherapy at 15 mg/kg (Part A) 20 B) on Days 8 first 21‐day...
1. The ferritin heavy chain (FHC) has a vital impact on follicular development in geese, due to its ability regulate apoptosis of granulosa cells (GCs) and atresia. However, specific regulatory mechanisms remain unclear. present study characterised how FHC regulates oxidative stress, cell proliferation goose GCs by interfering with overexpressing the
330 Background: Increased platelet-derived growth factor receptor alpha (PDGFRα) expression is linked to epithelial-mesenchymal transition in pancreatic cancer. Olaratumab (O) a fully human monoclonal antibody against PDGFRα previously approved for the treatment of advanced soft tissue sarcoma. Here, we report initial safety and antitumor activity data O combination with nab-paclitaxel + gemcitabine (nPG) first-line metastatic cancer patients (pts). Methods: In this 3+3 dose escalation...
Abstract Background Olaratumab, a fully human monoclonal antibody, selectively binds to platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on pharmacokinetics (PK) doxorubicin safety alone in combination with doxorubicin. Methods open‐label randomized phase 1 trial enrolled 49 patients ages 27 83 metastatic or locally advanced soft tissue sarcoma (STS). Patients participated 21‐day treatment cycles (up 8) until they met...
10541 Background: Olaratumab (O), a PDGFRα antagonist, is targeted human IgG1 monoclonal antibody that specifically binds PDGFRα, blocking PDGF-AA, -BB, and -CC binding receptor activation, has improved survival outcomes in adults with advanced sarcoma. Methods: This ongoing Phase 1, multicenter, dose-escalation study (NCT02677116) enrolled patients (pts) aged < 18 years, diagnosis of relapsed or refractory solid tumors, to 2 dose levels (Parts A B) O combined fixed doses standard...
Abstract Background: Olaratumab (olara), an IgG1 monoclonal antibody, blocks platelet-derived growth factor receptor (PDGFR) α activation. In a randomized Phase 2 study, olara plus doxorubicin (dox) improved overall survival in advanced soft tissue sarcoma (STS) patients (pts). The aim of this study (JGDM, NCT02783599) was to further evaluate potential biomarkers and the mechanism action pts with STS. Methods: Pts potentially resectable STS received monotherapy for one cycle followed by up 6...